On December 15, 2017, Teva Pharmaceuticals (TEVA) announced the exclusive launch of the generic version of 300 mg Viread tablets in the United States. TEVA stock gained nearly 7.6% on the day. The Vanguard FTSE All-World ex-US ETF (VEU) rose by ~0.22% on the day. VEU holds ~0.07% of its total portfolio holdings in TEVA.

TEVA Stock Price Rises on Generic Launch of Viread

Viread is the registered trademark of Gilead Sciences (GILD) for Tenofovir disoproxil fumurate medication, which is used for the treatment of chronic Hepatitis B and HIV (human immunodeficiency virus). Gilead’s patent on Viread expired on December 15, 2017. Viread received FDA (US Food and Drug Administration) approval in 2001. Teva and Gilead entered a patent settlement deal in 2013, which included Gilead’s HIV antivirals Truvada and Atripla as well, in addition to Viread. The generic version launches of the other two drugs are slated for fiscal 2018. Teva had a number of new product launches planned for 2017, as shown in the diagram. However, the company witnessed a delay in certain launches. As a result, it saw lower-than-expected sales contributions from the new launches.

During its recent quarterly results on November 2, 2017, Teva reduced its full fiscal 2017 guidance on its sales contribution from new product launches to $400 million from $500 million.

What is Tenofovir disoproxil fumurate?

Tenofovir disoproxil fumarate tablets are used for the treatment of HIV-1 infection for patients over two years old and the treatment of chronic Hepatitis B in adults and pediatric patients who are 12 years old or older. The medication is indicated for use in combination with other ARV (antiretroviral) drugs. As of October 2017, Viread sales amounted to approximately $762 million in the United States, as per IMS data.

Merck (MRK) and Bristol-Myers Squibb (BMY) are the two other major players in the HIV drugs market in the United States.

Latest articles

25 Jun

Gold Breaches $1,400: What’s the Next Stop?

WRITTEN BY Anuradha Garg

Gold is now trading close to a six-year high following the Fed’s dovish pivot at its June policy meeting. After being range-bound for the last five years, gold has finally broken out and its outlook is bullish.

Shares of the J.M. Smucker Company (SJM) are up 29.8% year-to-date as of June 24 and have outperformed the broader markets. The company's acquisition of Ainsworth Pet Nutrition and its focus on high-growth categories via divestitures have supported its stock so far this year.

On June 25, General Motors (GM), America’s largest auto company, announced its plan to invest $20 million into its Arlington Assembly plant in Texas, according to Reuters. With the new investment, the company aims to upgrade its equipment before launching its full-size SUVs.

Shares of high-growth technology company ServiceNow (NOW) have gained close to 16.0% since April 2019. It's gained over 60.0% since the start of 2019. It also had an encouraging run in 2018, when it gained 32.0% in market value.

25 Jun

Ford to Announce Q2 US Sales on July 3: What to Expect

WRITTEN BY Jitendra Parashar

Earlier today, Ford (F) said that it would announce its second-quarter US sales data on July 3. In the first quarter, the company reported a 1.6% YoY decline in its US sales to 590,249 vehicle units. During the first quarter, Ford’s truck sales rose by 4.1%, and its SUV sales went up by 5.0% on a YoY basis.

On June 25, Credit Suisse initiated coverage on Chipotle Mexican Grill with an “outperform” rating and a target price of $870—a return potential of 20.1% from its stock price of $724.13 on June 24.